CN103087984B - A kind of have the Chinese medicine composition and application thereof that promote mescenchymal stem cell proliferation function - Google Patents
A kind of have the Chinese medicine composition and application thereof that promote mescenchymal stem cell proliferation function Download PDFInfo
- Publication number
- CN103087984B CN103087984B CN201110337580.XA CN201110337580A CN103087984B CN 103087984 B CN103087984 B CN 103087984B CN 201110337580 A CN201110337580 A CN 201110337580A CN 103087984 B CN103087984 B CN 103087984B
- Authority
- CN
- China
- Prior art keywords
- stem cell
- stem cells
- mescenchymal stem
- chinese medicine
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*c(cc1)ccc1C(OC(C(CC=C(C)C)=C(*)CC1O)=C1C1=O)=C1N=C Chemical compound C*c(cc1)ccc1C(OC(C(CC=C(C)C)=C(*)CC1O)=C1C1=O)=C1N=C 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to the combination of a kind of Chinese medical extract, comprise Icaritin and rhodioside, there is the pharmacological action promoting mescenchymal stem cell propagation.Mescenchymal stem cell comprises umbilical cord mesenchymal stem cells and autologous bone marrow mesenchymal stem cells.The research of the compound that the present invention relates to stem cells hyperplasia mechanism is significant.The invention still further relates to these compounds and related compound thereof and promote the purposes in stem cells hyperplasia medicine preparation stem cells hyperplasia promotor and in preparation.Another aspect of the present invention relate to mescenchymal stem cell structure medicine effect preliminary screening with evaluate in apply, for the new drug development of illustrating and having an independent intellectual property right of herbal medicine efficacy mechanism indicates new direction.
Description
Technical field
The invention belongs to cell biology, relate to a kind of purposes of Chinese medicine composition, be specifically related to Icaritin and Root of Kirilow Rhodiola is impelling the purposes in mescenchymal stem cell propagation.The invention still further relates to the purposes of this Chinese medicine composition in preparation treatment cell injury disease.
Background technology
Stem cell is a kind of initiating cell with self-renewal capacity and multi-lineage potential, under given conditions, can also breed also directed differentiation and become different functioning cells.Therefore the research of stem cell is to the renewal of each histoorgan of life entity and injury repairing, plays a part very Chinese medicine, becomes unique hope of the many disease that cannot cure, particularly cell and tissue disappearance or injury disease.Stem cell comprises embryonic stem cell and adult stem cell, and embryonic stem cell, due to ethics problem, makes it apply and is subject to great restriction; And adult stem cell is owing to can be divided into functioning cell and tissue, for the widespread use of stem cell provides the foundation; For research Mammals early development provides good external model; Cell replacement therapy for numerous disease provides new cell derived; Also indicate that the development of modern biology and the research and development of novel drugs enter the new epoch.
Up to the present, only have a small amount of adult tissue stem cell, can cultivate by time limit serum-free amplification in vitro, but need to add different somatomedins, signaling molecule etc. carry out genetic regulation.Obviously, autologous and amplification in vitro culturing stem cells, needs more effective, safer cell culture technology.
Herba Epimedii (HerbaEpimedii) is Berberidaceae barrenwort, the effect such as have kidney invigorating and YANG supporting, dispel rheumatism.Modern pharmacological research proves, Herba Epimedii contains special chemical composition and significant biological activity, is a kind ofly to have the important ability extensively having good gift activity.In Herba Epimedii, flavonoid drugs has treatment cardiovascular and cerebrovascular diseases, prevents and treats the pharmacological action of osteoporosis etc.
Root of Kirilow Rhodiola system red-spotted stonecrop (Crassulaceae) section Rhodida plant is perennial herb or semishrub plant, is mainly distributed in the Himalayas in the Northern Hemisphere, the northwestward, Asia and North America height above sea level in the area of 1600-4000 rice.Root of Kirilow Rhodiola medicinal history is long, have the title of " gold ginseng " " Radix Rhodiolae ".It is the dry root and rhizome of crassulaceae plants Radix Rhodiolae that pharmacopeia records Root of Kirilow Rhodiola, and its property is sweet, bitter, put down, and benefiting QI for activating blood circulation, promotes blood circulation and relievings asthma, and can be used for qi deficiency to blood stasis, Obstruction of qi in the chest and cardialgia, stroke hemiplegia and indolent and listless asthma.Modern pharmacological research shows, the biological activity of Root of Kirilow Rhodiola is inseparable with contained number of chemical composition.
Rhodioside is the natural product of separating-purifying from Root of Kirilow Rhodiola, is a kind of monomeric compound, is one of effective constituent of Root of Kirilow Rhodiola, and the relevant section of part belongs to Chinese medicine also containing rhodioside, and chemical structural formula is as follows:
Summary of the invention
The object of this invention is to provide the Chinese medicine composition with stem cells hyperplasia effect.Chinese medicine composition provided by the invention can as stem cells hyperplasia promotor and for the preparation of the medicine promoting stem cells hyperplasia.Also may be used for scientific research, for research provides a large amount of stem cell.Chinese medicine composition provided by the invention can promote the reparation of stem cells hyperplasia and functioning cell, can be used in the research of stem cells hyperplasia mechanism.
The shown composition that this law provides is by following preparation process:
Icarin ultrasonic dissolution, in the least possible methyl alcohol, slowly adds the damping fluid of cellulase while stirring, and 37 DEG C of reactions are spent the night.The structural glucose of icarin and rhamnosyl are fully hydrolyzed, and extraction into ethyl acetate hydrolysate, Rotary Evaporators volatilizes and obtains Icaritin.Studies have reported that, in Herba Epimedii extract body, pharmacological evaluation display has gonadotropic Effect, and can make female mice uterus weight, estradiol content raises.Icaritin has the pharmacologically active of estrogen-like effects, this kind of natural phant compound with estrogen activity, has the effects such as anti-oxidant, angiogenesis inhibitor, anticancer differentiation.To hormone dependent cancer, cardiovascular disorder and postmenopausal osteoporosis and climacterium uncomfortable disease, early senile dementia have good preventive and therapeutic action.
The separation purification method of rhodioside monomer: Root of Kirilow Rhodiola powder is raw material, take water as solvent multistage microwave amplifier rhodioside, optimal processing parameter is: liquid-solid ratio 20: 1, soak time 1.5h, low power microwave process 60S, magnetic agitation 15min, extract 2 times, extraction yield can reach 90%.Pharmacological action: the ability of anti-hypoxia, antifatigue effect and external scavenging hydroxyl; To cardiovascular provide protection: the increase that the interleukin-1 beta that rhodioside can suppress Ischemia and Reperfusion in vivo in Rats to cause is expressed, reduce cerebral ischemia and play the cerebrovascular effect of protection in the expression paying close attention to TNF-α in tissues following MCAO in rats; By suppressing the expression of blood vessel ACE, can resist myocardial ischemia to a certain extent; Improve body immunity.
The present inventor finds in test, the composition of Icaritin and rhodioside has its increment effect of promotion to the human mesenchymal stem cell of vitro culture under finite concentration and proportioning, these cells are made to continue to keep vegetative state, and the speed of growth of more traditional cultural method cell is faster, cytoactive is higher.
Method of the present invention comprises following content:
Mescenchymal stem cell antiproliferative agent is the material that can increase mescenchymal stem cell quantity, such as, by stimulating proliferation, Inhibited differentiation and prevent mescenchymal stem cell death from increasing mescenchymal stem cell quantity.
Chinese medicine composition of the present invention comprises Icaritin and rhodioside.Extract Icaritin and rhodioside according to preceding method, its preferably combination ratio is 5: 1.
Chinese medicine composition consumption of the present invention: join in basic medium according to the ratio of 1%.Basic medium comprises DMEM/F12,1640, α MEM etc.
Data of the present invention shows, uses drug regimen of the present invention can play promoter action to the multiplication culture of autologous bone marrow mesenchymal stem cells, umbilical cord mesenchymal stem cells.Microscopic observation, use drug regimen of the present invention that mescenchymal stem cell can be made to keep greater activity, rate of propagation increases substantially, and prevents it from breaking up.It is all significant that the present invention carries out drug screening to the clinical application of mesenchymal stem cell transplantation and use mescenchymal stem cell.
Stem cell of the present invention urgees the propagation that multiplication agent may be used for stem cell, it is characterized in that, is contacted with stem cell by described Chinese medicine composition, promotes the propagation of stem cell.Use the occasion of stem cells hyperplasia agent provided by the invention in vitro, use after micromolecular compound provided by the invention is dissolved in suitable solution.Described suitable solution, comprises the substratum such as DMEM.
Mescenchymal stem cell of the present invention, comprises umbilical cord mesenchymal stem cells and autologous bone marrow mesenchymal stem cells.
Chinese medicine composition stem cell provided by the present invention urgees multiplication agent can directly administration, uses as conventional dose.In such use, described stem cells hyperplasia agent with Chinese medical extract provided by the invention for activeconstituents.Stem cell provided by the invention urgees multiplication agent can contain Chinese medical extract provided by the invention separately, or the mixture that Chinese medical extract provided by the invention forms according to specified proportion.
The present invention also provides a kind of method of culturing stem cells, is included in Chinese medicine composition of the present invention and deposits in case, culturing stem cells.
Accompanying drawing explanation
Fig. 1 is the promoter action that Icaritin and rhodioside are bred umbilical cord mesenchymal stem cells
Embodiment
In following embodiment, urge multiplication agent stem cell of the present invention and deposit in case, cultivate and obtain stem cell.The present invention will be described in more detail to enumerate embodiment below, but the present invention is not limited to these embodiments.
Embodiment 1
By Icaritin and rhodioside, according to the ratio mixing of 5: 1, be dissolved in DMEM/F12 substratum that (ultimate density is: Icaritin: 5uM; Rhodioside: 1uM).With this culture medium culturing umbilical cord mesenchymal stem cells.Mescenchymal stem cell (obtaining from umbilical cord according to a conventional method) is incubated in serum-free conventional medium (conventional medium comprises DMEM/F12,1640, α MEM etc.).Experiment is grouped into: medium controls (not adding Chinese medicine composition); Substratum+Chinese medicine composition.Cultivate and add MTT (5mg/ml) 10ul after four days, after hatching 4h, add lysate (10%SDS, 0.1%NH
4cl) 100ul, overnight incubation, in 490nm light-metering absorption value.
As shown in Figure 1, the height of histogram represents chemiluminescence intensity, is directly proportional to cell count.This shows, urge the existence of multiplication agent at Chinese medicine composition under, umbilical cord mesenchymal stem cells propagation has the increase of 30%, confirms that this Chinese medicine composition has the effect promoting propagation to mescenchymal stem cell.
Claims (3)
1. have the traditional Chinese medicine extract composition promoting mescenchymal stem cell proliferation function, it is characterized in that: described traditional Chinese medicine extract composition is made up of following raw material: Icaritin and rhodioside, ratio is 5:1.
2. a method for external promotion mescenchymal stem cell propagation, is characterized in that: to comprise ratio be cultivate mescenchymal stem cell in the culture system of the Icaritin of 5:1 and the traditional Chinese medicine extract composition of rhodioside with the addition of.
3. the method for external promotion mescenchymal stem cell propagation according to claim 2, is characterized in that: described source for mesenchymal stem cells comprises the umbilical cord of people, autologous bone marrow or placenta tissue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110337580.XA CN103087984B (en) | 2011-11-01 | 2011-11-01 | A kind of have the Chinese medicine composition and application thereof that promote mescenchymal stem cell proliferation function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110337580.XA CN103087984B (en) | 2011-11-01 | 2011-11-01 | A kind of have the Chinese medicine composition and application thereof that promote mescenchymal stem cell proliferation function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103087984A CN103087984A (en) | 2013-05-08 |
| CN103087984B true CN103087984B (en) | 2016-03-23 |
Family
ID=48201118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110337580.XA Active CN103087984B (en) | 2011-11-01 | 2011-11-01 | A kind of have the Chinese medicine composition and application thereof that promote mescenchymal stem cell proliferation function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103087984B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106566805A (en) * | 2016-11-01 | 2017-04-19 | 浙江译美生物科技有限公司 | Traditional Chinese medicinal complex and preparation method thereof and human mesenchymal stem cell medium |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107189981B (en) * | 2017-06-07 | 2020-01-21 | 广东医科大学 | Application of HDAC6 inhibitor in bone marrow mesenchymal stem cell transplantation |
| CN107496490B (en) * | 2017-09-25 | 2018-09-11 | 安徽金源药业有限公司 | A kind of Herba Epimedii rhodiola rosea formulated product and preparation method thereof |
| CN108379277A (en) * | 2018-02-14 | 2018-08-10 | 重庆大学 | Application of the rhodioside in the drug for preparing treatment diabetic wounds ulcer |
| CN109294980B (en) * | 2018-10-15 | 2021-07-20 | 雷桅 | Application of rhodiola rosea and salidroside in directional differentiation of stem cells into myocardial-like cells |
| CN110420222A (en) * | 2019-07-31 | 2019-11-08 | 杭州荣泽生物科技有限公司 | A kind of rhodioside joint mesenchymal stem cell injection and preparation method thereof for cardiomyopathy |
| CN113662985B (en) * | 2021-09-07 | 2022-06-24 | 北京中医药大学 | Traditional Chinese medicine composition with effect of promoting directional differentiation of stem cells into myocardial cells, traditional Chinese medicine effective component composition and application thereof |
| CN115645450B (en) * | 2022-10-09 | 2023-11-03 | 雷桅 | Application of rhodiola rosea or salidroside in preparation of preparation for protecting and/or regulating extracellular exosomes |
-
2011
- 2011-11-01 CN CN201110337580.XA patent/CN103087984B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| 中药促进间充质干细胞的增殖与分化;王艳春等;《中国组织工程研究与临床康复》;20110507;第15卷(第19期);3594-3597 * |
| 淫羊藿苷促进羊骨髓间充质干细胞的增殖和成骨分化;吴涛等;《中国组织工程研究与临床康复》;20090507;第13卷(第19期);3725-3729 * |
| 红景天苷对人骨髓间充质干细胞增殖及分泌的影响;李新永;《临床合理用药》;20110331;第4卷(第3C期);24-26 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106566805A (en) * | 2016-11-01 | 2017-04-19 | 浙江译美生物科技有限公司 | Traditional Chinese medicinal complex and preparation method thereof and human mesenchymal stem cell medium |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103087984A (en) | 2013-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103087984B (en) | A kind of have the Chinese medicine composition and application thereof that promote mescenchymal stem cell proliferation function | |
| Zheng et al. | Antihyperglycemic activity of Selaginella tamariscina (Beauv.) spring | |
| Zhao et al. | Rutin protects human periodontal ligament stem cells from TNF-α induced damage to osteogenic differentiation through suppressing mTOR signaling pathway in inflammatory environment | |
| CN109294980B (en) | Application of rhodiola rosea and salidroside in directional differentiation of stem cells into myocardial-like cells | |
| CN104109145A (en) | Flavonoid structure based hydrogen sulfide donor derivative and application in treatment of neuroinflammation related diseases thereof | |
| CN101225374B (en) | Use of common stonecrop herb and salidroside in stem cell oriented differentiation to hepatocyte lineage | |
| KR20160064966A (en) | Medical composition and applications thereof used for secondary chemotherapy drugs | |
| EP3406258B1 (en) | Medicament for use in treating gout | |
| CN113952378B (en) | Extraction method of lamiophlomis rotata glycoside and application of medicine or health-care product for preventing and treating hepatic fibrosis | |
| EP3339285A1 (en) | A compound isolated from isodon forrestii var. forrestii and preparation method and applications thereof | |
| CN102007110A (en) | Novel flavonol compounds, a bioactive extract/fraction from ulmus wallichiana and its compounds for prevention for treatment of osteo-health related disorders | |
| Goswami et al. | Pharmacological Significance of Catharanthus roseus in Cancer Management: A Review | |
| CN104962515A (en) | Application of rhizome panacis majoris saponin inducing stem cells differentiating hepatic cells and hepatosis curing medicine | |
| CN1281616C (en) | Compound extracted from xanthoceras sorbifolia shells and stems, extraction method and application | |
| CN102477041B (en) | Preparation method of cepharanthine hydrochloride | |
| CN100571698C (en) | Extract of valid target in cudrania tricuspidata total flavone and preparation method thereof | |
| CN108159337B (en) | Pharmaceutical composition for treating viral hepatitis B or C | |
| CN105560302B (en) | Application of geranium water extract in preparation of anti-angiogenesis drugs | |
| CN1709903A (en) | Saponin compound and use of its glucoside in preparing medicine for treating neure injure | |
| CN102119953A (en) | Application of euphorbia humifusa wild extract | |
| CN113368090B (en) | Application of 3, 4-seco cycloartenane type tetracyclic triterpene compound or pharmaceutically acceptable salt thereof in preparation of anticancer drugs | |
| CN117624269A (en) | Pyranoside compound extracted from cyclocarya paliurus, extraction method thereof and application of pyranoside compound in anti-prostate cancer drugs | |
| CN116270787B (en) | Application of Chinese and western compound medicine in preparation of leukemia treatment medicine | |
| CN114891001B (en) | Sophocarpine derivative, and preparation method and application thereof | |
| CN109985061B (en) | Application of dendrobe polysaccharide in preparation of medicine for preventing and/or treating prostatic hyperplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| DD01 | Delivery of document by public notice |
Addressee: Beijing QMLC Stem Cell Technology Co., Ltd. Document name: Notification of Publication of the Application for Invention |
|
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 100084, C building, Tsinghua Science and technology building, No. 1 Zhongguancun East Road, Beijing, Haidian District, 301 Applicant after: Beijing QMLC Stem Cell Technology Co., Ltd. Address before: 100097 Beijing city Haidian District minzhuang Road No. 3, Tsinghua Science Park building 204 Yuquan Huigu 7 Applicant before: Beijing QMLC Stem Cell Technology Co., Ltd. |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |